File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients

TitleTelbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients
Authors
DiBisceglie A, ALai, CLGane, EChen, YCThongsawat, SWang, YMChen, YGHeathcote, EJZeuzem, SRasenack, JBzowej, NHan, SHNaoumov, NHwang, SGLim, SGChao, GCFielman, BABrown, NAStudy Group The GLOBE,
Issue Date2006
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA, 27-31 October 2006. In Hepatology, 2006, v. 44 n. 4, Suppl 1, p. 230A-231A, abstract no. 112 How to Cite?
DOI: http://dx.doi.org/10.1002/hep.21395
Persistent Identifierhttp://hdl.handle.net/10722/101994
ISSN
0270-9139
2021 Impact Factor: 17.298
2020 SCImago Journal Rankings: 5.488

 

DC FieldValueLanguage
dc.contributor.authorDiBisceglie A, Aen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorGane, Een_HK
dc.contributor.authorChen, YCen_HK
dc.contributor.authorThongsawat, Sen_HK
dc.contributor.authorWang, YMen_HK
dc.contributor.authorChen, YGen_HK
dc.contributor.authorHeathcote, EJen_HK
dc.contributor.authorZeuzem, Sen_HK
dc.contributor.authorRasenack, Jen_HK
dc.contributor.authorBzowej, Nen_HK
dc.contributor.authorHan, SHen_HK
dc.contributor.authorNaoumov, Nen_HK
dc.contributor.authorHwang, SGen_HK
dc.contributor.authorLim, SGen_HK
dc.contributor.authorChao, GCen_HK
dc.contributor.authorFielman, BAen_HK
dc.contributor.authorBrown, NAen_HK
dc.contributor.authorStudy Group The GLOBE,en_HK
dc.date.accessioned2010-09-25T20:12:49Z-
dc.date.available2010-09-25T20:12:49Z-
dc.date.issued2006en_HK
dc.identifier.citationThe 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA, 27-31 October 2006. In Hepatology, 2006, v. 44 n. 4, Suppl 1, p. 230A-231A, abstract no. 112en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/101994-
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.titleTelbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patientsen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=44&issue=Suppl 1&spage=231A&epage=&date=2006&atitle=Telbivudine+Globe+Trial:+Maximal+Early+HBV+Suppression+is+Predictive+of+Optimal+Two-year+Efficacy+in+Nucleoside-treated+Hepatitis+B+Patientsen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.doi10.1002/hep.21395-
dc.identifier.hkuros133900en_HK
dc.identifier.volume44en_HK
dc.identifier.issue4, Suppl 1en_HK
dc.identifier.spage230Aen_HK
dc.identifier.epage231A-
dc.identifier.issnl0270-9139-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats